TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* Chronic HCV infection (≥ 6 months)~* Serum HCV RNA of ≥ 1 × 104 IU/mL are documented~* Hepatitis C virus GT1~* Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or host-targeting antivirals for HCV~* Non-cirrhosis patients: Non-cirrhosis is defined (1)Fibroscan defined as: ˂ 14.6 kPa during screening period, or liver biopsy determined 1 year before recruiting (Metavir score ˂ 3);(2) during screening period 9.6\<Fibroscan indicator ≤12.9, liver biopsy need to confirm non-cirrhosis.~* Others as specified in the detailed protocol~Exclusion Criteria:~* Patients with Fibroscan detection value \> 12.9 kPa, or histologic examination for liver cirrhosis patients~* Presence or history of non-hepatitis C chronic liver disease (e.g. HH, AIH, Wilson's disease, α1 antitrypsin deficiency, drug- or toxin-induced liver disease)~* History of liver cell cancer, or suspected hepatocellular carcinoma (HCC) patients before or during screening , or imaging studies found suspicious nodules, or AFP \> 50 ng/mL~* Positive hepatitis A antibody，positive hepatitis B surface antigen，HIV antibody~* Presence or history of nervous system diseases and/or mental illness, inability to control oneself or express oneself.~* Patients with obvious cardiovascular dysfunction~* Pregnant or nursing female, nor unwilling to take reliable contraception~* Others as specified in the detailed protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Danoprevir, Ritonavir, Peg-IFN,RBV (Type: EXPERIMENTAL): Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subjects with 5 to 20 clinically typical, visible and, discrete, nonhyperkeratotic and non-hypertrophic AKs within a selected treatment area of sun-damaged skin on either:~* The full face~* The full balding scalp~* A contiguous area of approximately 250 cm2 on trunk or extremities~Exclusion Criteria:~Location of the treatment area (full face, full balding scalp or chest) within 5 cm of an incompletely healed wound or within 5 cm of a suspected basal cell carcinoma (BCC) or SCC.~Previously assigned treatment in this clinical trial or previously participated in a clinical trial in the LEO 43204 programme.~Treatment with ingenol mebutate gel in the selected treatment area within the last 12 months~Lesions in the treatment area that have: atypical clinical appearance (e.g. cutaneous horns) and/or, recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 43204, 0.018% once daily for 3 days (Type: EXPERIMENTAL): None
- LEO 43204, 0.037% once daily for 3 days (Type: EXPERIMENTAL): None
- LEO 43204, 0.1% once daily for 3 days (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~1. Participants, or their legally appointed and authorized representatives, must provide written and signed informed consent form (ICF)/assent~2. Participants must be aged ≥ 12 years at the time of informed consent and, as applicable, assent~3. Participants must have a documented diagnosis of hereditary angioedema type 1 (HAE-1)/hereditary angioedema type 2 (HAE-2)~4. Participants must:~   1. Experience a minimum of 2 HAE attacks (confirmed by the Investigator) during the Screening Period~  2. Be willing to complete the participant reported outcomes (PRO) assessments throughout the study~5. Participants must have access to, and the ability to use acute medication(s) to treat angioedema attacks~Exclusion Criteria~1. Concurrent diagnosis of any other type of recurrent angioedema, including acquired, idiopathic angioedema or HAE with normal C1-INH (also known as HAE Type III)~2. Any clinically-significant abnormalities in screening laboratory values that would render a participant unsuitable for inclusion in the study~3. Treatment with another investigational drug or biological agent within 1 month or 5 half-lives, whichever is longer, of Screening~4. Participated in a prior ISIS 721744 study~5. Exposure to any of the following medications:~   1. Angiotensin-converting enzyme (ACE) inhibitors or any estrogen containing medications with systemic absorption within 4 weeks prior to Screening~  2. Chronic prophylaxis with Takhzyro, Haegarda, Cinryze and Ruconest or Orladeyo within 5 half-lives prior to Screening~  3. Oligonucleotides (including small interfering ribonucleic acid \[siRNA\]) within 4 months of Screening if single dose received, or within 12 months of Screening if multiple doses received. This exclusion does not apply to vaccines~6. Recent history (3 years) of, or current drug or alcohol abuse

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donidalorsen: Cohort A (Type: EXPERIMENTAL): Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
- Donidalorsen: Cohort B (Type: EXPERIMENTAL): Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
- Placebo: Cohort A (Type: PLACEBO_COMPARATOR): Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.
- Placebo: Cohort B (Type: PLACEBO_COMPARATOR): Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Miniscrews as Anchorage Device for Orthodontic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents in need of orthodontic treatment with fixed appliance including extractions of the maxillary first premolars~* Need for Anchorage reinforcement~* Permanent dentition including the maxillary second molars in occlusion (DS4M2 according to Björk)~* Regular dental care in Sweden since the age of three.~Exclusion Criteria:~* Experience of previous orthodontic treatment~* Need for orthognathic surgery~* Need for maximum anchorage.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- Group A - Miniscrews (Type: EXPERIMENTAL): Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal). Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with miniscrews (Spider Screw K1 short neck). Miniscrews are placed buccally between the maxillary second premolar and the first molar after topical anesthesia (buccal) and injection (buccal). Miniscrews are placed when space closure starts. Space closure is performed as en masse retraction. Miniscrew are immediately loaded with 150g Nickel Titanium coil springs.
- Group B - Molarblock (Type: ACTIVE_COMPARATOR): Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal. Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with molarblocks - a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar. Molarblocks are installed from the beginning of leveling and alignment. Space closure is performed as en masse retraction with type one active tie-backs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over the age of 18 year.~* Patients diagnosed with advanced melanoma.~* Patients that are considered candidates for ipilimumab therapy.~* Patients able to understand and willing to sign a written informed consent documents.~* Patients willing to have regular blood draws, one before treatment and four during or after treatment.~Exclusion Criteria:~* Patients under the age of 18.~* Patients with Stage I or II, melanoma who are not candidates for Ipilimumab.~* Patients that have received systemic treatments within four weeks prior to the beginning of treatment.~* Women that are pregnant or nursing.~* Patients taking immunosuppressive medications.~* Patients with active autoimmune disease.~* Patients with known sensitivity to retinoic acid derivatives.~* Patients with aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin \> 2.5 × ULN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Ipilimumab (Type: ACTIVE_COMPARATOR): Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
- VESANOID (Type: EXPERIMENTAL): Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Desflurane Anesthesia Versus TIVA-TCI in Patients Undergoing Ophthalmic Ambulatory Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-60 years patients undergoing selective ophthalmic ambulatory surgery；~* ASA I and II~* duration of anesthesia at least 30min~* without apparent organ comorbidities~* sign the informed consent form~Exclusion Criteria:~* equal or greater than ASA III~* has a history of dementia，psychiatric disorders or central nervous system diseases~* taking sedatives, antidepressant or glucocorticoid~* without family members~* has cardiac, respiratory，liver，kidney comorbidities~* uncontrolled hypertension（\>180/100mmHg）~* laryngeal mask fail to insert, and change to tracheal intubation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Group TIVA (Type: EXPERIMENTAL): method of anesthesia is total intravenous anesthesia(TIVA) and maintenance with propofol Cp 2-4 μg/ml and remifentanil 2-4 ng/ml in target controlled infusion(TCI) during the procedure
- Group Des (Type: EXPERIMENTAL): method of anesthesia is inhalation anesthesia and maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Between 20 and 79 years (at the time of giving informed consent).~* Sex: Either sex.~* Admission status: Outpatients.~* Patients requiring treatment for hypertension according to the JSH 2004 hypertension therapy guidelines before beginning this study~* Patients who have not used any calcium antagonists for at least 4 weeks before the beginning of this study.~* Patients who are scheduled to undergo elective PCI.~Exclusion Criteria:~* Patients with acute coronary syndrome (ACS).~* Patients who have experienced Q-wave myocardial infarction within 4 weeks before beginning this study.~* Patients with renal dysfunction (serum creatinine \>2.0 mg/dL).~* Patients in whom PCI is unsuccessful.~* Patients with cardiogenic shock.~* Patients with moderate or severe congestive heart failure.~* Patients with 50% or more stenosis of the main trunk of the left coronary artery.~* Patients with other problems whom the investigator considers unsuitable for this study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Amlodipine
- 2 (Type: ACTIVE_COMPARATOR): Azelnidipine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~Generally healthy; LDL-C level in serum or plasma ≥ 100 mg/dL and \< 190 mg/dL at Screening.~Exclusion criteria:~* LDL-C ≥ 160 mg/dL at Screening if more than 2 major Coronary Heart Disease risk factors, as defined in National Cholesterol Education Program guidelines.~* Receiving treatment of any kind for hyperlipidemia within 6 weeks of enrollment.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo - Alirocumab (Type: EXPERIMENTAL): Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18-60~* Patients with a diagnosis of multiple sclerosis~Exclusion Criteria:~* Patients with a history or presence of chronic disease of the immune system other than MS~* Patients with a history or presence of malignancy, pulmonary or heart disease, etc.~* Pregnant or nursing (lactating) women~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- FTY720 0.5 mg (Type: EXPERIMENTAL): FTY720
- FTY720 1.25 mg (Type: EXPERIMENTAL): FTY720
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women diagnosed with Parkinson's Disease (Hoehn Yahr 2-4, age \>18 years) or men and women diagnosed with Alzheimer's Disease. Include patients older than 50 years with mild to moderate Alzheimer's disease according to ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale; ADAS≥12) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB; CDR≤2).~* Patients with stable treatments and clinical course~Exclusion Criteria:~* Inability or unwillingness to give written informed consent~* History of stroke, severe brain trauma, toxic drug exposure~* Neurological examination which indicate to Parkinson-Plus syndrome (i.e., pyramidal, cerebellar and autonomic dysfunction findings and gaze paralysis) for PD~* Uncontrolled Type 1 or type 2 diabetes~* Diarrhea (defined as more than 2 stool per day) within 7 days before enrolment~* Chronic kidney disease with an estimated glomerular filtration rate \<60 ml/min/1.73m2~* Significant cardiovascular co-morbidity (i.e. heart failure, documented coronary artery disease, valvular heart disease)~* Patients with active bronchial asthma~* Patients with phenylketonuria (contraindicated for NAC)~* Patients with histamine intolerance~* Clinically significant TSH level outside the normal range (0.04-6 mU/L)~* Known allergy for substances used in the study~* Concomitant medication use: Self-administration of dietary supplements such as any vitamins, omega-3 products, or plant stanol/sterol products within 1 month; Use of an antimicrobial agent in the 4 weeks preceding randomization~* Active smokers consuming \>10 cigarettes/day~* Alcohol consumption over 192 grams for men and 128 grams for women per week~* Patients considered as inappropriate for this study for any reason (patients unable to undergo MRI study, noncompliance etc.)~* Active participation in another clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Subjects will take a mixture of placebo as powder dissolved in water by mouth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability of Pimasertib in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed solid tumors, either refractory to standard therapy or for which no effective standard therapy is available, with a measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1~* An Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than or equal to (\<=) 1~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Disease conditions or concomitant medication that may significantly influence the conduct of the trial or an abnormal electrocardiogram (ECG) or blood pressure at Screening as defined in the protocol~* Treatment with strong inhibitors or inducers of cytochrome P450 2C19 (CYP2C19) and CYP3A4 including fruit juices or beverages containing these substances~* History of prior mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) kinase (MEK) inhibitor exposure (including, pimasertib) or progression of disease on MEK inhibitors~* Evidence of a retinal vein occlusion (RVO) on fluorescein angiogram or a history of RVO~* Life expectancy of less than 12 weeks~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pimasertib Capsule/Pimasertib Tablet (Type: EXPERIMENTAL): None
- Pimasertib Tablet/Pimasertib Capsule (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics as a Prophylaxis to Prevent Clinical Manifestations of Oral Candidosis in Patients With Sjogren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary or scondary Sjogren's syndrome~Exclusion Criteria:~* allergy to milk derivatives previous intake of antifungals

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Probiotic group (Type: EXPERIMENTAL): Probiotic complex capsule taken twice daily for 5weeks
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo capsule taken twice daily for 5 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete